Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in ...
ENDPOINTS NEWS5d
Im­muneer­ing touts pos­i­tive pan­cre­at­ic can­cer da­ta for MEK in­hibitor
Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...
New treatment option shows promise for severe hypertrophic cardiomyopathy in children
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...
Immuneering Co. (NASDAQ:IMRX) Receives $12.80 Consensus PT from Analysts
Immuneering Co. (NASDAQ:IMRX – Get Free Report) has been given a consensus rating of “Hold” by the eight analysts that are ...
Geode Capital Management LLC Decreases Stock Holdings in Immuneering Co. (NASDAQ:IMRX)
Geode Capital Management LLC reduced its holdings in shares of Immuneering Co. (NASDAQ:IMRX – Free Report) by 5.5% during the ...
Business Wire13d
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of R…
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...
EurekAlert!5d
New treatment option for severe hypertrophic cardiomyopathy in children shows promise
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...